Selective HLA class I antigen loss identified by testing leukemic cells with HLA class I antigen-typing sera in CDC assay
Case no. . | Leukemic subtype . | Sample type . | Normal cells . | . | . | . | Tumor cells . | . | . | . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | A . | A . | B . | B . | A . | A . | B . | B . | ||||||
1 | CLL | BL | 10 | 31 | 38 | 40 | NR* | NR* | 38 | 40 | ||||||
2 | AML | BL | 24 | 31 | 60 | H | 24 | 31 | 60 | H | ||||||
3 | CLL | BL | 2 | 3 | 7 | 51 | 2 | 3 | 7 | 51 | ||||||
4 | CLL | BL | 1 | 2 | 5 | 8 | 1 | 2 | 5 | 8 | ||||||
5 | CLL | BL | 3 | 10 | 35 | 44 | 3 | 10 | 35 | 44 | ||||||
6 | AML | BL | 24 | 32 | 39 | 57 | 24 | 32 | 39 | 57 | ||||||
7 | CLL | BL | 2 | 10 | 8 | 14 | 2 | 10 | NR* | 14 | ||||||
8 | ALL | BL | 2 | 3 | 60 | H | 2 | 3 | 60 | H | ||||||
9 | CLL | BL | 1 | 3 | 35 | 40 | 1 | 3 | 35 | 40 | ||||||
11 | AML | BL | 1 | 2 | 7 | 60 | 1 | 2 | 7 | 60 | ||||||
12 | CLL | BL | 3 | 23 | 7 | 44 | 3 | 23 | 7 | 44 | ||||||
13 | CLL | BL | 1 | 24 | 8 | 18 | 1 | 24 | 8 | 18 | ||||||
14 | CLL | BL | 24 | 32 | 35 | 51 | 24 | 32 | 35 | 51 | ||||||
15 | AML | BL | ND | ND | ND | ND | 3 | 11 | 35 | 38 | ||||||
16 | CLL | BL | 2 | 24 | 13 | 18 | 2 | 24 | 13 | 18 | ||||||
17 | ALL | BL | 1 | H | 5 | 7 | 1 | H | 5 | 7 | ||||||
18 | ALL | BL | 2 | 33 | 7 | 14 | 2 | 33 | 7 | 14 | ||||||
21 | ALL | BL | ND | ND | ND | ND | 10 | 28 | 52 | H | ||||||
23 | AML | BL | 2 | 32 | 8 | 17 | 2 | 32 | 8 | 17 | ||||||
26 | CLL | BL | 2 | H | 7 | 44 | 2 | H | 7 | 44 | ||||||
27 | CLL | BL | 2 | H | 8 | 44 | 2 | H | 8 | 44 | ||||||
28 | CLL | BL | 2 | 32 | 18 | 35 | 2 | 32 | 18 | 35 | ||||||
29 | AML | BL | 2 | 28 | 13 | 18 | 2 | NR* | 13 | 18 | ||||||
30 | AML | BL | 2 | H | 17 | 42 | 2 | H | 17 | 42 | ||||||
31 | CLL | BL | 11 | 33 | 35 | 57 | 11 | 33 | 35 | 57 | ||||||
32 | AML | BL | 2 | 3 | 39 | 51 | 2 | 3 | 39 | 51 | ||||||
33 | AML | BL | 2 | 23 | 35 | 44 | 2 | 23 | 35 | 44 | ||||||
34 | AML | BM | 1 | 2 | 13 | 60 | 1 | 2 | 13 | 60 | ||||||
38 | CLL | BL | 1 | 2 | 8 | 12 | NR* | 2 | 8 | 12 | ||||||
40 | AML | BL | 3 | 29 | 44 | 55 | 3 | 29 | 44 | 55 | ||||||
41 | CLL | BL | 3 | 29 | 51 | 60 | 3 | 29 | 51 | 60 | ||||||
42 | CLL | BL | 2 | 19 | 39 | H | 2 | 19 | 39 | H | ||||||
43 | AML | BL | ND | ND | ND | ND | 11 | 24 | 35 | 62 | ||||||
44 | AML | BL | 2 | 29 | 35 | 51 | 2 | 29 | NR* | 51 | ||||||
46 | AML | BL | ND | ND | ND | ND | 3 | 25 | 22 | 35 | ||||||
47 | CLL | BL | 1 | 3 | 7 | 8 | 1 | 3 | 7 | 8 | ||||||
48 | AML | BL | ND | ND | ND | ND | 1 | 2 | 8 | 60 |
Case no. . | Leukemic subtype . | Sample type . | Normal cells . | . | . | . | Tumor cells . | . | . | . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | A . | A . | B . | B . | A . | A . | B . | B . | ||||||
1 | CLL | BL | 10 | 31 | 38 | 40 | NR* | NR* | 38 | 40 | ||||||
2 | AML | BL | 24 | 31 | 60 | H | 24 | 31 | 60 | H | ||||||
3 | CLL | BL | 2 | 3 | 7 | 51 | 2 | 3 | 7 | 51 | ||||||
4 | CLL | BL | 1 | 2 | 5 | 8 | 1 | 2 | 5 | 8 | ||||||
5 | CLL | BL | 3 | 10 | 35 | 44 | 3 | 10 | 35 | 44 | ||||||
6 | AML | BL | 24 | 32 | 39 | 57 | 24 | 32 | 39 | 57 | ||||||
7 | CLL | BL | 2 | 10 | 8 | 14 | 2 | 10 | NR* | 14 | ||||||
8 | ALL | BL | 2 | 3 | 60 | H | 2 | 3 | 60 | H | ||||||
9 | CLL | BL | 1 | 3 | 35 | 40 | 1 | 3 | 35 | 40 | ||||||
11 | AML | BL | 1 | 2 | 7 | 60 | 1 | 2 | 7 | 60 | ||||||
12 | CLL | BL | 3 | 23 | 7 | 44 | 3 | 23 | 7 | 44 | ||||||
13 | CLL | BL | 1 | 24 | 8 | 18 | 1 | 24 | 8 | 18 | ||||||
14 | CLL | BL | 24 | 32 | 35 | 51 | 24 | 32 | 35 | 51 | ||||||
15 | AML | BL | ND | ND | ND | ND | 3 | 11 | 35 | 38 | ||||||
16 | CLL | BL | 2 | 24 | 13 | 18 | 2 | 24 | 13 | 18 | ||||||
17 | ALL | BL | 1 | H | 5 | 7 | 1 | H | 5 | 7 | ||||||
18 | ALL | BL | 2 | 33 | 7 | 14 | 2 | 33 | 7 | 14 | ||||||
21 | ALL | BL | ND | ND | ND | ND | 10 | 28 | 52 | H | ||||||
23 | AML | BL | 2 | 32 | 8 | 17 | 2 | 32 | 8 | 17 | ||||||
26 | CLL | BL | 2 | H | 7 | 44 | 2 | H | 7 | 44 | ||||||
27 | CLL | BL | 2 | H | 8 | 44 | 2 | H | 8 | 44 | ||||||
28 | CLL | BL | 2 | 32 | 18 | 35 | 2 | 32 | 18 | 35 | ||||||
29 | AML | BL | 2 | 28 | 13 | 18 | 2 | NR* | 13 | 18 | ||||||
30 | AML | BL | 2 | H | 17 | 42 | 2 | H | 17 | 42 | ||||||
31 | CLL | BL | 11 | 33 | 35 | 57 | 11 | 33 | 35 | 57 | ||||||
32 | AML | BL | 2 | 3 | 39 | 51 | 2 | 3 | 39 | 51 | ||||||
33 | AML | BL | 2 | 23 | 35 | 44 | 2 | 23 | 35 | 44 | ||||||
34 | AML | BM | 1 | 2 | 13 | 60 | 1 | 2 | 13 | 60 | ||||||
38 | CLL | BL | 1 | 2 | 8 | 12 | NR* | 2 | 8 | 12 | ||||||
40 | AML | BL | 3 | 29 | 44 | 55 | 3 | 29 | 44 | 55 | ||||||
41 | CLL | BL | 3 | 29 | 51 | 60 | 3 | 29 | 51 | 60 | ||||||
42 | CLL | BL | 2 | 19 | 39 | H | 2 | 19 | 39 | H | ||||||
43 | AML | BL | ND | ND | ND | ND | 11 | 24 | 35 | 62 | ||||||
44 | AML | BL | 2 | 29 | 35 | 51 | 2 | 29 | NR* | 51 | ||||||
46 | AML | BL | ND | ND | ND | ND | 3 | 25 | 22 | 35 | ||||||
47 | CLL | BL | 1 | 3 | 7 | 8 | 1 | 3 | 7 | 8 | ||||||
48 | AML | BL | ND | ND | ND | ND | 1 | 2 | 8 | 60 |
Untouched leukemic cells and autologous lymphocytes were isolated using immunomagnetic procedure. HLA class I allospecificity expression was assessed by testing cells with HLA class I-typing sera in complement-dependent microcytotoxicity (CDC) assay.
H indicates a homozygous sample; ND, not done or not enough normal cells available; and NR, no reaction with the respective anti–HLA class I antisera.